Omnibio Spółka z Ograniczoną Odpowiedzialnością (KRS 0000737795, NIP 5252754681) is a Polish company, headquartered in Katowice, Śląskie voivodeship. OMNIBIO operates in: Other retail sale in non-specialised stores (PKD 47.19.Z). Industry: Retail trade. The company has been listed in the National Court Register since June 25, 2018. OMNIBIO's most recently reported net revenue was 24.4 K PLN for 2023.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Omnibio
Identity
- Name
- Omnibio Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 25, 2018
- Registry status as of
- November 21, 2025
- Latest entry
- July 19, 2024
- Founding act
- 15.06.2018 R.
Articles of association history (3)
- June 15, 2018: 15.06.2018 R.
- July 23, 2018: 23.07.2018 R., ZMIANA: §3
- September 4, 2018: 04.09.2018 R. REP.A NR 4903/2018, NOTARIUSZ ALEKSANDER DAWID, KANCELARIA NOTARIALNA W SIEMIANOWICACH ŚLĄSKICH UL. WALEREGO WRÓBLEWSKIEGO 67/5, 41-106 SIEMIANOWICE ŚLĄSKIE ZMIENIONO §2
Activities
Main activity
47.19.ZOther retail sale in non-specialised stores
Other activities
Address and contact
- Address
- UL. STAROMIEJSKA, 13A, 40-013, KATOWICE, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- KATOWICE
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 50.2180, 19.0232approx.
Risk and payment profile - Omnibio
Credibility rating
32.4 / 100
Poor credibility
Insolvency risk
Very low
Elevated threat
Closure risk
24
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/8 yrs
Board changes
0
0/8 yrs
PKD changes
0
0/8 yrs
Name changes
1
1/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2023
Current: E (32/100)
Trend: deteriorating (-15.4 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2023
Current: 298.66 PLN
Safe: 59.73 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Omnibio
Founded
June 25, 2018
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
KATOWICE
ŚLĄSKIE
Primary PKD
47.19.Z
Other retail sale in non-specialised stores
Share capital
5.0 K PLN
100 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
6 years
2018–2023 · profitable: 3/6
Registry entries
20
latest: July 19, 2024
Risk signals
Revenue
24.4 K PLN
2023
Net profit
-13.6 K PLN
2023
Assets
49.7 K PLN
2023
Equity
N/A
2023
EBITDA
N/A
2023
no depreciation data
Valuation
3.6 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Omnibio.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
